NFKB1 and diffuse large B-cell lymphoma: The antineoplastic effects of lenalidomide in ABC-subtype DLBCL were associated with direct targeting of IRF-4, leading to downregulation of NF-κB pathway activity and augmentation of the interferon pathway32,33.